LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China from Corxel Pharmaceuticals. The deal assigns Everest the rights and obligations under LENZ’s existing license agreement, making LENZ eligible for up to $85 million in remaining regulatory and sales milestones, plus tiered royalties on net sales.
Key figures
- Royalty rate
- mid single-digit to low double-digit
- Potential milestones usd
- 85000000
- Us presbyopia population
- 128 million
- Global presbyopia population
- 1.8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.